Topical ketoconazole, such as the 2% cream or shampoo, is generally considered low risk during pregnancy because it is not absorbed into the bloodstream in measurable amounts. Oral ketoconazole carries more concern due to its systemic effects, though the available human data has not confirmed an increased risk of birth defects. The distinction between topical and oral forms is the most important factor in evaluating safety.
Topical Forms Have Minimal Absorption
When ketoconazole is applied to the skin or scalp as a cream, shampoo, or foam, it stays local. Studies measuring blood levels after topical use find no detectable ketoconazole in plasma, even with repeated application. This means the drug essentially never reaches the developing fetus. For this reason, topical ketoconazole is placed in a lower risk tier than the oral tablet form.
That said, there are no well-controlled studies of topical ketoconazole specifically in pregnant women. The FDA labeling for the 2% shampoo states it “should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus,” which is standard regulatory language for drugs that lack formal pregnancy trials rather than an indication of known harm.
Oral Ketoconazole and Fetal Risk
The safety concerns around ketoconazole in pregnancy stem almost entirely from oral (systemic) use. In animal studies, rats given ketoconazole orally at 80 mg/kg/day, roughly 10 times the maximum recommended human oral dose, developed offspring with fused fingers and missing digits. However, these effects appeared at doses that also caused serious illness in the mother rats, making it difficult to separate direct fetal toxicity from the consequences of severe maternal sickness.
The mechanism behind these effects involves ketoconazole’s ability to block certain enzymes that help produce steroid hormones. At high systemic doses, the drug interferes with hormone pathways that are critical during fetal development. This hormone-disrupting effect is dose-dependent and tied to the amount of drug circulating in the blood, which is why topical application poses a fundamentally different risk profile than swallowing a tablet.
The largest human study on this topic, a population-based case-control study comparing over 22,000 infants born with congenital abnormalities to more than 38,000 healthy controls, found no increased rate of birth defects among mothers who took oral ketoconazole during pregnancy. The rate of oral ketoconazole exposure was identical in both groups (0.03%), producing a prevalence odds ratio of 0.8, meaning no signal of harm was detected. While reassuring, the number of exposed pregnancies was small, so the study can’t rule out very rare effects.
Why Oral Ketoconazole Is Rarely Prescribed Now
Separate from pregnancy concerns, the FDA has significantly restricted the use of oral ketoconazole tablets due to the risk of potentially fatal liver injury, dangerous drug interactions, and adrenal gland suppression. These risks apply to all patients, not just pregnant women. Oral ketoconazole is now reserved for serious fungal infections when no other antifungal will work. If you’re pregnant and being treated for a fungal infection, it’s very unlikely your provider would reach for oral ketoconazole in the first place.
Preferred Antifungals During Pregnancy
For common fungal infections like vaginal yeast infections, ringworm, or athlete’s foot, clotrimazole, miconazole, and nystatin are considered first-line treatments in pregnancy. These topical antifungals have longer track records of use in pregnant women and more established safety profiles. If you’re dealing with a scalp condition like seborrheic dermatitis and already using ketoconazole shampoo, the negligible absorption makes it a reasonable option to discuss with your provider, but alternatives exist if you prefer them.
Ketoconazole While Breastfeeding
Topical ketoconazole on the skin or scalp poses little to no risk to a breastfed infant. One study of a mother taking 200 mg orally found that an exclusively breastfed infant would receive roughly 0.4% of the mother’s weight-adjusted dose through breast milk, a very small amount. Still, because oral ketoconazole can affect liver enzymes, manufacturers recommend avoiding breastfeeding during oral treatment and for one day after the last dose.
One practical consideration: if you’re using a topical ketoconazole product, avoid applying it directly to the breast or nipple area while nursing. The infant could ingest the cream directly, and safer topical antifungals are available for that specific location. If a topical product is needed on the breast, water-miscible creams or gels are preferable to ointments, which can contain mineral paraffins that the infant may ingest.